Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance

Adaptive Biotechnologies CorpTrade
iShares Self-Driving EV and TechTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs iShares Self-Driving EV and Tech — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while iShares Self-Driving EV and Tech trades at $37.18. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.

ADPTIDRV
Market Cap
$4.04B
Sector
HealthSector/Thematic
52-Week High
$25.45$45.48
52-Week Low
$12.30$34.49
Enterprise Value
$4.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

iShares Self-Driving EV and Tech

IDRV trades at $37.24, down 0.35% on the day, with a bullish technical signal driven by moving averages. The stock is positioned near its pivot point of $37, with key resistance at $38 and support at $36. Recent news highlights strong global EV sales growth and China's ambitious 2030 fleet target, supporting the thematic focus of the fund.

The outlook for IDRV is supported by positive industry trends in electric vehicles, though the absence of key valuation and profitability ratios limits fundamental assessment. Risks include competitive pressures and regulatory changes, while analyst sentiment is mixed with a slight bullish bias. The stock's performance remains tied to broader EV market dynamics.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About iShares Self-Driving EV and Tech

IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.

Read more on IDRV